Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme, Inc. (“Marizyme”, OTCQB:MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™.
Related news for (MRZM)
- Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
- Marizyme CEO Delivers Business Update
- InvestmentPitch Media Video Features Marizyme’s CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
- The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News